Iradimed (IRMD) Cash & Equivalents (2013 - 2026)

Iradimed (IRMD) has 14 years of Cash & Equivalents data on file, last reported at $56.4 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $56.4 million, up 12.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $56.4 million (up 12.01% YoY), and the FY2025 annual result was $51.2 million, down 2.06% from the prior year.
• Cash & Equivalents climbed to $56.4 million in Q1 2026 per IRMD's latest filing, from $51.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $58.0 million in Q4 2022 and troughed at $42.8 million in Q1 2023.
• A 5-year average of $51.0 million and a median of $51.2 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents dropped 15.91% in 2023, then rose 12.01% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $58.0 million in 2022, then declined by 14.15% to $49.8 million in 2023, then increased by 4.97% to $52.2 million in 2024, then dropped by 2.06% to $51.2 million in 2025, then climbed by 10.19% to $56.4 million in 2026.
• Business Quant data shows IRMD's Cash & Equivalents at $56.4 million in Q1 2026, $51.2 million in Q4 2025, and $56.5 million in Q3 2025.